<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">31937935</PMID>
      <DateCompleted>
        <Year>2020</Year>
        <Month>05</Month>
        <Day>01</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>17</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1471-0080</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>21</Volume>
            <Issue>4</Issue>
            <PubDate>
              <Year>2020</Year>
              <Month>Apr</Month>
            </PubDate>
          </JournalIssue>
          <Title>Nature reviews. Molecular cell biology</Title>
          <ISOAbbreviation>Nat Rev Mol Cell Biol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>mTOR at the nexus of nutrition, growth, ageing and disease.</ArticleTitle>
        <Pagination>
          <StartPage>183</StartPage>
          <EndPage>203</EndPage>
          <MedlinePgn>183-203</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1038/s41580-019-0199-y</ELocationID>
        <Abstract>
          <AbstractText>The mTOR pathway integrates a diverse set of environmental cues, such as growth factor signals and nutritional status, to direct eukaryotic cell growth. Over the past two and a half decades, mapping of the mTOR signalling landscape has revealed that mTOR controls biomass accumulation and metabolism by modulating key cellular processes, including protein synthesis and autophagy. Given the pathway's central role in maintaining cellular and physiological homeostasis, dysregulation of mTOR signalling has been implicated in metabolic disorders, neurodegeneration, cancer and ageing. In this Review, we highlight recent advances in our understanding of the complex regulation of the mTOR pathway and discuss its function in the context of physiology, human disease and pharmacological intervention.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Grace Y</ForeName>
            <Initials>GY</Initials>
            <Identifier Source="ORCID">0000-0001-5463-3055</Identifier>
            <AffiliationInfo>
              <Affiliation>Whitehead Institute for Biomedical Research, Cambridge, MA, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Biology, Howard Hughes Medical Institute, Massachusetts Institute of Technology, Cambridge, MA, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Broad Institute, Cambridge, MA, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>The David H. Koch Institute for Integrative Cancer Research at MIT, Cambridge, MA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sabatini</LastName>
            <ForeName>David M</ForeName>
            <Initials>DM</Initials>
            <Identifier Source="ORCID">0000-0002-1446-7256</Identifier>
            <AffiliationInfo>
              <Affiliation>Whitehead Institute for Biomedical Research, Cambridge, MA, USA. sabatini@wi.mit.edu.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Biology, Howard Hughes Medical Institute, Massachusetts Institute of Technology, Cambridge, MA, USA. sabatini@wi.mit.edu.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Broad Institute, Cambridge, MA, USA. sabatini@wi.mit.edu.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>The David H. Koch Institute for Integrative Cancer Research at MIT, Cambridge, MA, USA. sabatini@wi.mit.edu.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>R01 CA103866</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>T32 GM007287</GrantID>
            <Acronym>GM</Acronym>
            <Agency>NIGMS NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>F31 CA232340</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R37 AI047389</GrantID>
            <Acronym>AI</Acronym>
            <Agency>NIAID NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 CA129105</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>01</Month>
          <Day>14</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Nat Rev Mol Cell Biol</MedlineTA>
        <NlmUniqueID>100962782</NlmUniqueID>
        <ISSNLinking>1471-0072</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>EC 2.7.1.1</RegistryNumber>
          <NameOfSubstance UI="C546842">MTOR protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D058570">TOR Serine-Threonine Kinases</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <CommentsCorrectionsList>
        <CommentsCorrections RefType="ErratumIn">
          <RefSource>Nat Rev Mol Cell Biol. 2020 Jan 31;:</RefSource>
          <PMID Version="1">32005970</PMID>
        </CommentsCorrections>
      </CommentsCorrectionsList>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001343" MajorTopicYN="N">Autophagy</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008659" MajorTopicYN="N">Metabolic Diseases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009752" MajorTopicYN="N">Nutritional Status</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014176" MajorTopicYN="N">Protein Biosynthesis</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058570" MajorTopicYN="N">TOR Serine-Threonine Kinases</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="accepted">
          <Year>2019</Year>
          <Month>11</Month>
          <Day>26</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>1</Month>
          <Day>16</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2020</Year>
          <Month>5</Month>
          <Day>2</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>1</Month>
          <Day>16</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">31937935</ArticleId>
        <ArticleId IdType="mid">NIHMS1559311</ArticleId>
        <ArticleId IdType="pmc">PMC7102936</ArticleId>
        <ArticleId IdType="doi">10.1038/s41580-019-0199-y</ArticleId>
        <ArticleId IdType="pii">10.1038/s41580-019-0199-y</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Vezina C, Kudelski A &amp; Sehgal SN
Rapamycin (AY-22,989), a new antifungal antibiotic I. Taxonomy of
the producing streptomycete and isolation of the active
principle. J. Antibiot
28, 721–726
(1975).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1102508</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martel RR, Klicius J &amp; Galet S
Inhibition of the immune response by rapamycin, a new antifungal
antibiotic. Can J. Physiol. Pharmacol
55, 48–51
(1977).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">843990</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eng CP, Sehgal SN &amp; Vezina C
Activity of rapamycin (AY-22,989) against transplanted
tumors. J. Antibiot
37, 1231–1237
(1984).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6501094</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Houchens DP, Ovejera AA, Riblet SM &amp; Slagel DE
Human brain tumor xenografts in nude mice as a chemotherapy
model. Eur. J. Cancer Clin. Oncol
19, 799–805
(1983).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6683650</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bierer BE
et al.
Two distinct signal transmission pathways in T lymphocytes are
inhibited by complexes formed between an immunophilin and either FK506 or
rapamycin. Proc. Natl Acad. Sci. USA
87, 9231–9235
(1990).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC55138</ArticleId>
            <ArticleId IdType="pubmed">2123553</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chung J, Kuo CJ, Crabtree GR &amp; Blenis J
Rapamycin–FKBP specifically blocks growth-dependent
activation of and signaling by the 70 kd S6 protein kinases.
Cell
69, 1227–1236
(1992).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1377606</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brown EJ
et al.
A mammalian protein targeted by G1-arresting
rapamycin–receptor complex. Nature
369, 756–758
(1994).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8008069</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sabatini DM, Erdjument-Bromage H, Lui M, Tempst P &amp; Snyder SH
RAFT1: a mammalian protein that binds to FKBP12 in a
rapamycin-dependent fashion and is homologous to yeast TORs.
Cell
78, 35–43
(1994).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7518356</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sabers CJ
et al.
Isolation of a protein target of the FKBP12–rapamycin
complex in mammalian cells. J. Biol. Chem
270, 815–822
(1995).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7822316</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Heitman J, Movva NR &amp; Hall MN
Targets for cell cycle arrest by the immunosuppressant rapamycin
in yeast. Science
253, 905–909
(1991).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1715094</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cafferkey R
et al.
Dominant missense mutations in a novel yeast protein related to
mammalian phosphatidylinositol 3-kinase and VPS34 abrogate rapamycin
cytotoxicity. Mol. Cell Biol
13, 6012–6023
(1993).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC364661</ArticleId>
            <ArticleId IdType="pubmed">8413204</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kunz J
et al.
Target of rapamycin in yeast, TOR2, is an essential
phosphatidylinositol kinase homolog required for G1
progression. Cell
73, 585–596
(1993).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8387896</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Helliwell SB
et al.
TOR1 and TOR2 are structurally and functionally similar but not
identical phosphatidylinositol kinase homologues in yeast.
Mol. Biol. Cell
5, 105–118
(1994).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC301013</ArticleId>
            <ArticleId IdType="pubmed">8186460</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Keith CT &amp; Schreiber SL
PIK-related kinases: DNA repair, recombination, and cell cycle
checkpoints. Science
270, 50 (1995).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7569949</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim DH
et al.
GβL, a positive regulator of the rapamycin-sensitive
pathway required for the nutrient-sensitive interaction between raptor and
mTOR. Mol. Cell
11, 895–904
(2003).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12718876</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim DH
et al.
mTOR interacts with raptor to form a nutrient-sensitive complex
that signals to the cell growth machinery.
Cell
110, 163–175
(2002).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12150925</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hara K
et al.
Raptor, a binding partner of target of rapamycin (TOR), mediates
TOR action. Cell
110, 177–189
(2002).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12150926</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang H
et al.
mTOR kinase structure, mechanism and regulation.
Nature
497, 217–223
(2013).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4512754</ArticleId>
            <ArticleId IdType="pubmed">23636326</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guertin DA
et al.
Ablation in mice of the mTORC components raptor, rictor, or mLST8
reveals that mTORC2 is required for signaling to Akt-FOXO and PKCα,
but not S6K1. Dev. Cell
11, 859–871
(2006).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17141160</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schalm SS, Fingar DC, Sabatini DM &amp; Blenis J
TOS motif-mediated raptor binding regulates 4E-BP1 multisite
phosphorylation and function. Curr. Biol
13, 797–806
(2003).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12747827</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nojima H
et al.
The mammalian target of rapamycin (mTOR) partner, raptor, binds
the mTOR substrates p70 S6 kinase and 4E-BP1 through their TOR signaling
(TOS) motif. J. Biol. Chem
278, 15461–15464
(2003).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12604610</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sancak Y
et al.
PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein
kinase. Mol. Cell
25, 903–915
(2007).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17386266</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vander Haar E, Lee S-I, Bandhakavi S, Griffin TJ &amp; Kim D-H
Insulin signalling to mTOR mediated by the Akt/PKB substrate
PRAS40. Nat. Cell Biol
9, 316–323
(2007).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17277771</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Peterson TR
et al.
DEPTOR is an mTOR inhibitor frequently overexpressed in multiple
myeloma cells and required for their survival.
Cell
137, 873–886
(2009).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2758791</ArticleId>
            <ArticleId IdType="pubmed">19446321</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yip CK, Murata K, Walz T, Sabatini DM &amp; Kang SA
Structure of the human mTOR complex I and its implications for
rapamycin inhibition. Mol. Cell
38, 768–774
(2010).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2887672</ArticleId>
            <ArticleId IdType="pubmed">20542007</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aylett CH
et al.
Architecture of human mTOR complex 1.
Science
351, 48–52
(2016).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26678875</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang H
et al.
Mechanisms of mTORC1 activation by RHEB and inhibition by
PRAS40. Nature
552, 368–373
(2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5750076</ArticleId>
            <ArticleId IdType="pubmed">29236692</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hwang Y
et al.
Disruption of the scaffolding function of mLST8 selectively
inhibits mTORC2 assembly and function and suppresses mTORC2-dependent tumor
growth in vivo. Cancer Res.
79, 3178
(2019).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6606357</ArticleId>
            <ArticleId IdType="pubmed">31085701</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sarbassov DD
et al.
Rictor, a novel binding partner of mTOR, defines a
rapamycin-insensitive and raptor-independent pathway that regulates the
cytoskeleton. Curr. Biol
14, 1296–1302
(2004).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15268862</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jacinto E
et al.
Mammalian TOR complex 2 controls the actin cytoskeleton and is
rapamycin insensitive. Nat. Cell Biol
6, 1122–1128
(2004).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15467718</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Frias MA
et al.
mSin1 is necessary for Akt/PKB phosphorylation, and its isoforms
define three distinct mTORC2s. Curr. Biol
16, 1865–1870
(2006).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16919458</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jacinto E
et al.
SIN1/MIP1 maintains rictor–mTOR complex integrity and
regulates Akt phosphorylation and substrate specificity.
Cell
127, 125–137
(2006).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16962653</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang Q, Inoki K, Ikenoue T &amp; Guan KL
Identification of Sin1 as an essential TORC2 component required
for complex formation and kinase activity. Genes
Dev. 20,
2820–2832
(2006).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1619946</ArticleId>
            <ArticleId IdType="pubmed">17043309</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pearce LR
et al.
Identification of Protor as a novel Rictor-binding component of
mTOR complex-2. Biochem. J
405, 513–522
(2007).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2267312</ArticleId>
            <ArticleId IdType="pubmed">17461779</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Woo SY
et al.
PRR5, a novel component of mTOR complex 2, regulates
platelet-derived growth factor receptor β expression and
signaling. J. Biol. Chem
282, 25604–25612
(2007).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17599906</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yuan H-X &amp; Guan K-L
The SIN1-PH domain connects mTORC2 to PI3K.
Cancer Discov. 5,
1127–1129
(2015). </Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4638136</ArticleId>
            <ArticleId IdType="pubmed">26526694</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen X
et al.
Cryo-EM structure of human mTOR complex 2.
Cell Res. 28,
518–528
(2018).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5951902</ArticleId>
            <ArticleId IdType="pubmed">29567957</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stuttfeld E
et al.
Architecture of the human mTORC2 core complex.
eLife
7, e33101 (2018).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5837792</ArticleId>
            <ArticleId IdType="pubmed">29424687</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sarbassov DD
et al.
Prolonged rapamycin treatment inhibits mTORC2 assembly and
Akt/PKB. Mol. Cell
22, 159–168
(2006).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16603397</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lamming DW
et al.
Rapamycin-induced insulin resistance is mediated by mTORC2 loss
and uncoupled from longevity. Science
335, 1638–1643
(2012).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3324089</ArticleId>
            <ArticleId IdType="pubmed">22461615</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thoreen CC
et al.
An ATP-competitive mammalian target of rapamycin inhibitor
reveals rapamycin-resistant functions of mTORC1. J.
Biol. Chem
284, 8023–8032
(2009).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2658096</ArticleId>
            <ArticleId IdType="pubmed">19150980</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kang SA
et al.
mTORC1 phosphorylation sites encode their sensitivity to
starvation and rapamycin. Science
341, 1236566
(2013).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3771538</ArticleId>
            <ArticleId IdType="pubmed">23888043</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Choo AY, Yoon S-O, Kim SG, Roux PP &amp; Blenis J
Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate
cell-type-specific repression of mRNA translation.
Proc. Natl Acad. Sci. USA
105, 17414–17419
(2008).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2582304</ArticleId>
            <ArticleId IdType="pubmed">18955708</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Buttgereit F &amp; Brand MD
A hierarchy of ATP-consuming processes in mammalian
cells. Biochem. J
312, 163–167
(1995).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1136240</ArticleId>
            <ArticleId IdType="pubmed">7492307</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brunn GJ
et al.
Phosphorylation of the translational repressor PHAS-I by the
mammalian target of rapamycin. Science
277, 99–101
(1997).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9204908</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gingras AC
et al.
Regulation of 4E-BP1 phosphorylation: a novel two-step
mechanism. Genes Dev. 13,
1422–1437
(1999).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC316780</ArticleId>
            <ArticleId IdType="pubmed">10364159</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hara K
et al.
Regulation of eIF-4E BP1 phosphorylation by mTOR.
J. Biol. Chem
272, 26457–26463
(1997).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9334222</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pullen N
et al.
Phosphorylation and activation of p70s6k by PDK1.
Science
279, 707 (1998).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9445476</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Burnett PE, Barrow RK, Cohen NA, Snyder SH &amp; Sabatini DM
RAFT1 phosphorylation of the translational regulators p70 S6
kinase and 4E-BP1. Proc. Natl Acad. Sci.
USA
95, 1432–1437
(1998).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC19032</ArticleId>
            <ArticleId IdType="pubmed">9465032</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ruvinsky I
et al.
Ribosomal protein S6 phosphorylation is a determinant of cell
size and glucose homeostasis. Genes Dev.
19, 2199–2211
(2005). </Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1221890</ArticleId>
            <ArticleId IdType="pubmed">16166381</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chauvin C
et al.
Ribosomal protein S6 kinase activity controls the ribosome
biogenesis transcriptional program.
Oncogene
33, 474 (2013).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23318442</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hannan KM
et al.
mTOR-dependent regulation of ribosomal gene transcription
requires S6K1 and is mediated by phosphorylation of the carboxy-terminal
activation domain of the nucleolar transcription factor UBF.
Mol. Cell Biol
23, 8862–8877
(2003).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC262650</ArticleId>
            <ArticleId IdType="pubmed">14612424</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mayer C, Zhao J, Yuan X &amp; Grummt I
mTOR-dependent activation of the transcription factor TIF-IA
links rRNA synthesis to nutrient availability. Genes
Dev. 18,
423–434
(2004).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC359396</ArticleId>
            <ArticleId IdType="pubmed">15004009</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Michels AA
et al.
mTORC1 directly phosphorylates and regulates human
MAF1. Mol. Cell Biol
30, 3749 (2010).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2916396</ArticleId>
            <ArticleId IdType="pubmed">20516213</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shor B
et al.
Requirement of the mTOR kinase for the regulation of Maf1
phosphorylation and control of RNA polymerase III-dependent transcription in
cancer cells. J. Biol. Chem
285, 15380–15392
(2010).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2865278</ArticleId>
            <ArticleId IdType="pubmed">20233713</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Holz MK, Ballif BA, Gygi SP &amp; Blenis J
mTOR and S6K1 mediate assembly of the translation preinitiation
complex through dynamic protein interchange and ordered phosphorylation
events. Cell
123, 569–580
(2005).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16286006</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dorrello NV
et al.
S6K1- and βTRCP-mediated degradation of PDCD4 promotes
protein translation and cell growth.
Science
314, 467–471
(2006).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17053147</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ma XM, Yoon SO, Richardson CJ, Julich K &amp; Blenis J
SKAR links pre-mRNA splicing to mTOR/S6K1-mediated enhanced
translation efficiency of spliced mRNAs.
Cell
133, 303–313
(2008).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18423201</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mieulet V
et al.
S6 kinase inactivation impairs growth and translational target
phosphorylation in muscle cells maintaining proper regulation of protein
turnover. Am. J. Physiol. Cell Physiol
293, C712–C722
(2007).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17494629</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pende M
et al.
S6K1–/–/S6K2–/–
mice exhibit perinatal lethality and rapamycin-sensitive 5ʹ-terminal
oligopyrimidine mRNA translation and reveal a mitogen-activated protein
kinase-dependent S6 kinase pathway. Mol. Cell
Biol
24, 3112–3124
(2004).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC381608</ArticleId>
            <ArticleId IdType="pubmed">15060135</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hsieh AC
et al.
The translational landscape of mTOR signalling steers cancer
initiation and metastasis. Nature
485, 55 (2012).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3663483</ArticleId>
            <ArticleId IdType="pubmed">22367541</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thoreen CC
et al.
A unifying model for mTORC1-mediated regulation of mRNA
translation. Nature
485, 109–113
(2012).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3347774</ArticleId>
            <ArticleId IdType="pubmed">22552098</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Horton JD, Goldstein JL &amp; Brown MS
SREBPs: activators of the complete program of cholesterol and
fatty acid synthesis in the liver. J. Clin.
Invest
109, 1125–1131
(2002).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC150968</ArticleId>
            <ArticleId IdType="pubmed">11994399</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Peterson TR
et al.
mTOR complex 1 regulates lipin 1 localization to control the
SREBP pathway. Cell
146, 408–420
(2011).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3336367</ArticleId>
            <ArticleId IdType="pubmed">21816276</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Porstmann T
et al.
SREBP activity is regulated by mTORC1 and contributes to
Akt-dependent cell growth. Cell Metab.
8, 224–236
(2008).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2593919</ArticleId>
            <ArticleId IdType="pubmed">18762023</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Duvel K
et al.
Activation of a metabolic gene regulatory network downstream of
mTOR complex 1. Mol. Cell
39, 171–183
(2010). </Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2946786</ArticleId>
            <ArticleId IdType="pubmed">20670887</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim JE &amp; Chen J
Regulation of peroxisome proliferator-activated receptor-γ
activity by mammalian target of rapamycin and amino acids in
adipogenesis. Diabetes
53, 2748–2756
(2004).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15504954</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ben-Sahra I, Hoxhaj G, Ricoult SJH, Asara JM &amp; Manning BD
mTORC1 induces purine synthesis through control of the
mitochondrial tetrahydrofolate cycle.
Science
351, 728–733
(2016).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4786372</ArticleId>
            <ArticleId IdType="pubmed">26912861</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ben-Sahra I, Howell JJ, Asara JM &amp; Manning BD
Stimulation of de novo pyrimidine synthesis by growth signaling
through mTOR and S6K1. Science
339, 1323–1328
(2013).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3753690</ArticleId>
            <ArticleId IdType="pubmed">23429703</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Robitaille AM
et al.
Quantitative phosphoproteomics reveal mTORC1 activates de novo
pyrimidine synthesis. Science
339, 1320–1323
(2013).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23429704</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Valvezan AJ
et al.
mTORC1 couples nucleotide synthesis to nucleotide demand
resulting in a targetable metabolic vulnerability.
Cancer Cell
32, 624–638
(2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5687294</ArticleId>
            <ArticleId IdType="pubmed">29056426</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>He L
et al.
mTORC1 promotes metabolic reprogramming by the suppression of
GSK3-dependent Foxk1 phosphorylation. Mol.
Cell
70, 949–960
(2018).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6591025</ArticleId>
            <ArticleId IdType="pubmed">29861159</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zid BM
et al.
4E-BP extends lifespan upon dietary restriction by enhancing
mitochondrial activity in Drosophila. Cell
139, 149–160
(2009).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2759400</ArticleId>
            <ArticleId IdType="pubmed">19804760</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cunningham JT
et al.
mTOR controls mitochondrial oxidative function through a
YY1–PGC-1α transcriptional complex.
Nature
450, 736–740
(2007).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18046414</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim J, Kundu M, Viollet B &amp; Guan KL
AMPK and mTOR regulate autophagy through direct phosphorylation
of Ulk1. Nat. Cell Biol
13, 132–141
(2011).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3987946</ArticleId>
            <ArticleId IdType="pubmed">21258367</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hosokawa N
et al.
Nutrient-dependent mTORC1 association with the
ULK1–Atg13–FIP200 complex required for
autophagy. Mol. Biol. Cell
20, 1981–1991
(2009). </Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2663915</ArticleId>
            <ArticleId IdType="pubmed">19211835</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ganley IG
et al.
ULK1·ATG13·FIP200 complex mediates mTOR signaling
and is essential for autophagy. J. Biol.
Chem
284, 12297–12305
(2009).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2673298</ArticleId>
            <ArticleId IdType="pubmed">19258318</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dikic I &amp; Elazar Z
Mechanism and medical implications of mammalian
autophagy. Nat. Rev. Mol. Cell Biol
19, 349–364
(2018).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29618831</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim YM
et al.
mTORC1 phosphorylates UVRAG to negatively regulate autophagosome
and endosome maturation. Mol. Cell
57, 207–218
(2015).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4304967</ArticleId>
            <ArticleId IdType="pubmed">25533187</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Settembre C
et al.
A lysosome-to-nucleus signalling mechanism senses and regulates
the lysosome via mTOR and TFEB. EMBO J.
31, 1095–1108
(2012).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3298007</ArticleId>
            <ArticleId IdType="pubmed">22343943</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martina JA, Chen Y, Gucek M &amp; Puertollano R
MTORC1 functions as a transcriptional regulator of autophagy by
preventing nuclear transport of TFEB.
Autophagy
8, 903–914
(2012).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3427256</ArticleId>
            <ArticleId IdType="pubmed">22576015</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roczniak-Ferguson A
et al.
The transcription factor TFEB links mTORC1 signaling to
transcriptional control of lysosome homeostasis.
Sci. Signal
5, ra42
(2012).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3437338</ArticleId>
            <ArticleId IdType="pubmed">22692423</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu L
et al.
Termination of autophagy and reformation of lysosomes regulated
by mTOR. Nature
465, 942 (2010).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2920749</ArticleId>
            <ArticleId IdType="pubmed">20526321</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Odle RI
et al.
An mTORC1-to-CDK1 switch maintains autophagy suppression during
mitosis. Mol Cell, 10.1016/j.molcel.2019.10.016
(2019).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.molcel.2019.10.016</ArticleId>
            <ArticleId IdType="pmc">PMC6964153</ArticleId>
            <ArticleId IdType="pubmed">31733992</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wyant GA
et al.
mTORC1 activator SLC38A9 is required to efflux essential amino
acids from lysosomes and use protein as a nutrient.
Cell
171, 642–654
(2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5704964</ArticleId>
            <ArticleId IdType="pubmed">29053970</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wyant GA
et al.
NUFIP1 is a ribosome receptor for starvation-induced
ribophagy. Science
360, 751–758
(2018).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6020066</ArticleId>
            <ArticleId IdType="pubmed">29700228</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guo JY
et al.
Autophagy provides metabolic substrates to maintain energy charge
and nucleotide pools in Ras-driven lung cancer cells.
Genes Dev. 30,
1704–1717
(2016).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5002976</ArticleId>
            <ArticleId IdType="pubmed">27516533</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kraft C, Deplazes A, Sohrmann M &amp; Peter M
Mature ribosomes are selectively degraded upon starvation by an
autophagy pathway requiring the Ubp3p/Bre5p ubiquitin
protease. Nat. Cell Biol
10, 602–610
(2008).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18391941</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>An H &amp; Harper JW
Systematic analysis of ribophagy in human cells reveals bystander
flux during selective autophagy. Nat. Cell
Biol
20, 135–143
(2018).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5786475</ArticleId>
            <ArticleId IdType="pubmed">29230017</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Larsson C
Protein kinase C and the regulation of the actin
cytoskeleton. Cell Signal.
18, 276–284
(2006).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16109477</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu L, Das S, Losert W &amp; Parent CA
mTORC2 regulates neutrophil chemotaxis in a cAMP- and
RhoA-dependent fashion. Dev. Cell
19, 845–857
(2010).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3071587</ArticleId>
            <ArticleId IdType="pubmed">21145500</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schmidt KM
et al.
Inhibition of mTORC2/RICTOR impairs melanoma hepatic
metastasis. Neoplasia
20, 1198–1208
(2018).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6224335</ArticleId>
            <ArticleId IdType="pubmed">30404068</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morrison Joly M
et al.
Two distinct mTORC2-dependent pathways converge on Rac1 to drive
breast cancer metastasis. Breast Cancer
Res. 19, 74
(2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5493112</ArticleId>
            <ArticleId IdType="pubmed">28666462</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ikenoue T, Inoki K, Yang Q, Zhou X &amp; Guan KL
Essential function of TORC2 in PKC and Akt turn motif
phosphorylation, maturation and signalling. EMBO
J. 27,
1919–1931
(2008).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2486275</ArticleId>
            <ArticleId IdType="pubmed">18566587</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li X &amp; Gao T
mTORC2 phosphorylates protein kinase Cζ to regulate its
stability and activity. EMBO Rep.
15, 191–198
(2014).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3989865</ArticleId>
            <ArticleId IdType="pubmed">24375676</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>García-Martínez JM &amp; Alessi DR
mTOR complex 2 (mTORC2) controls hydrophobic motif
phosphorylation and activation of serum- and glucocorticoid-induced protein
kinase 1 (SGK1). Biochem. J
416, 375 (2008).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18925875</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sarbassov DD, Guertin DA, Ali SM &amp; Sabatini DM
Phosphorylation and regulation of Akt/PKB by the
rictor–mTOR complex. Science
307, 1098–1101
(2005).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15718470</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Webb AE &amp; Brunet A
FOXO transcription factors: key regulators of cellular quality
control. Trends Biochem. Sci
39, 159–169
(2014).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4021867</ArticleId>
            <ArticleId IdType="pubmed">24630600</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hoxhaj G
et al.
Direct stimulation of NADP+ synthesis through
Akt-mediated phosphorylation of NAD kinase.
Science
363, 1088–1092
(2019).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7261235</ArticleId>
            <ArticleId IdType="pubmed">30846598</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Inoki K, Li Y, Zhu T, Wu J &amp; Guan KL
TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR
signalling. Nat. Cell Biol
4, 648–657
(2002).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12172553</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Humphrey SJ
et al.
Dynamic adipocyte phosphoproteome reveals that Akt directly
regulates mTORC2. Cell Metab.
17, 1009–1020
(2013).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3690479</ArticleId>
            <ArticleId IdType="pubmed">23684622</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ebner M, Sinkovics B, Szczygieł M, Ribeiro DW &amp; Yudushkin I
Localization of mTORC2 activity inside cells.
J. Cell Biol
216, 343 (2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5294791</ArticleId>
            <ArticleId IdType="pubmed">28143890</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Inoki K, Li Y, Xu T &amp; Guan KL
Rheb GTPase is a direct target of TSC2 GAP activity and regulates
mTOR signaling. Genes Dev.
17, 1829–1834
(2003).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC196227</ArticleId>
            <ArticleId IdType="pubmed">12869586</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Long X, Lin Y, Ortiz-Vega S, Yonezawa K &amp; Avruch J
Rheb binds and regulates the mTOR kinase.
Curr. Biol
15, 702–713
(2005).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15854902</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sancak Y
et al.
The Rag GTPases bind raptor and mediate amino acid signaling to
mTORC1. Science
320, 1496–1501
(2008).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2475333</ArticleId>
            <ArticleId IdType="pubmed">18497260</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim E, Goraksha-Hicks P, Li L, Neufeld TP &amp; Guan KL
Regulation of TORC1 by Rag GTPases in nutrient
response. Nat. Cell Biol
10, 935–945
(2008). </Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2711503</ArticleId>
            <ArticleId IdType="pubmed">18604198</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dibble CC &amp; Manning BD
Signal integration by mTORC1 coordinates nutrient input with
biosynthetic output. Nat. Cell Biol
15, 555–564
(2013).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3743096</ArticleId>
            <ArticleId IdType="pubmed">23728461</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dibble CC
et al.
TBC1D7 is a third subunit of the TSC1–TSC2 complex
upstream of mTORC1. Mol. Cell
47, 535–546
(2012).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3693578</ArticleId>
            <ArticleId IdType="pubmed">22795129</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tee AR, Manning BD, Roux PP, Cantley LC &amp; Blenis J
Tuberous sclerosis complex gene products, tuberin and hamartin,
control mTOR signaling by acting as a GTPase-activating protein complex
toward Rheb. Curr. Biol
13, 1259–1268
(2003).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12906785</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Valvezan AJ &amp; Manning BD
Molecular logic of mTORC1 signalling as a metabolic
rheostat. Nat. Metab
1, 321–333
(2019).</Citation>
        </Reference>
        <Reference>
          <Citation>Garami A
et al.
Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP
signaling, is inhibited by TSC1 and 2. Mol.
Cell
11, 1457–1466
(2003).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12820960</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Manning BD, Tee AR, Logsdon MN, Blenis J &amp; Cantley LC
Identification of the tuberous sclerosis complex-2 tumor
suppressor gene product tuberin as a target of the phosphoinositide
3-kinase/Akt pathway. Mol. Cell
10, 151–162
(2002).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12150915</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Menon S
et al.
Spatial control of the TSC complex integrates insulin and
nutrient regulation of mTORC1 at the lysosome.
Cell
156, 771–785
(2014).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4030681</ArticleId>
            <ArticleId IdType="pubmed">24529379</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Demetriades C, Doumpas N &amp; Teleman AA
Regulation of TORC1 in response to amino acid starvation via
lysosomal recruitment of TSC2. Cell
156, 786–799
(2014). </Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4346203</ArticleId>
            <ArticleId IdType="pubmed">24529380</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Harrington LS
et al.
The TSC1–2 tumor suppressor controls insulin–PI3K
signaling via regulation of IRS proteins. J. Cell
Biol
166, 213–223
(2004).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2172316</ArticleId>
            <ArticleId IdType="pubmed">15249583</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shah OJ, Wang Z &amp; Hunter T
Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette
induces IRS1/2 depletion, insulin resistance, and cell survival
deficiencies. Curr. Biol
14, 1650–1656
(2004).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15380067</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Inoki K
et al.
TSC2 integrates Wnt and energy signals via a coordinated
phosphorylation by AMPK and GSK3 to regulate cell growth.
Cell
126, 955–968
(2006).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16959574</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee DF
et al.
IKKβ suppression of TSC1 links inflammation and tumor
angiogenesis via the mTOR pathway. Cell
130, 440–455
(2007).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17693255</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ma L, Chen Z, Erdjument-Bromage H, Tempst P &amp; Pandolfi PP
Phosphorylation and functional inactivation of TSC2 by Erk
implications for tuberous sclerosis and cancer pathogenesis.
Cell
121, 179–193
(2005).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15851026</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roux PP, Ballif BA, Anjum R, Gygi SP &amp; Blenis J
Tumor-promoting phorbol esters and activated Ras inactivate the
tuberous sclerosis tumor suppressor complex via p90 ribosomal S6
kinase. Proc. Natl Acad. Sci. USA
101, 13489–13494
(2004).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC518784</ArticleId>
            <ArticleId IdType="pubmed">15342917</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gwinn DM
et al.
AMPK phosphorylation of raptor mediates a metabolic
checkpoint. Mol. Cell
30, 214–226
(2008).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2674027</ArticleId>
            <ArticleId IdType="pubmed">18439900</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shaw RJ
et al.
The LKB1 tumor suppressor negatively regulates mTOR
signaling. Cancer Cell
6, 91–99
(2004).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15261145</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Inoki K, Zhu T &amp; Guan KL
TSC2 mediates cellular energy response to control cell growth and
survival. Cell
115, 577–590
(2003).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14651849</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Herzig S &amp; Shaw RJ
AMPK: guardian of metabolism and mitochondrial
homeostasis. Nat. Rev. Mol. Cell Biol
19, 121–135
(2018).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5780224</ArticleId>
            <ArticleId IdType="pubmed">28974774</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brugarolas J
et al.
Regulation of mTOR function in response to hypoxia by REDD1 and
the TSC1/TSC2 tumor suppressor complex. Genes
Dev. 18,
2893–2904
(2004).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC534650</ArticleId>
            <ArticleId IdType="pubmed">15545625</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>DeYoung MP, Horak P, Sofer A, Sgroi D &amp; Ellisen LW
Hypoxia regulates TSC1/2-mTOR signaling and tumor suppression
through REDD1-mediated 14–3–3 shuttling.
Genes Dev. 22,
239–251
(2008).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2192757</ArticleId>
            <ArticleId IdType="pubmed">18198340</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Demetriades C, Plescher M &amp; Teleman AA
Lysosomal recruitment of TSC2 is a universal response to cellular
stress. Nat. Commun
7, 10662 (2016).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4754342</ArticleId>
            <ArticleId IdType="pubmed">26868506</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Saveljeva S
et al.
Endoplasmic reticulum stress-mediated induction of SESTRIN 2
potentiates cell survival. Oncotarget
7, 12254–12266
(2016).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4914282</ArticleId>
            <ArticleId IdType="pubmed">26930721</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Feng Z
et al.
The regulation of AMPKβ1, TSC2, and PTEN expression by
p53: stress, cell and tissue specificity, and the role of these gene
products in modulating the IGF-1–AKT–mTOR
pathways. Cancer Res. 67,
3043–3053
(2007).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17409411</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Blommaart EF, Luiken JJ, Blommaart PJ, van Woerkom GM &amp; Meijer AJ
Phosphorylation of ribosomal protein S6 is inhibitory for
autophagy in isolated rat hepatocytes. J. Biol.
Chem
270, 2320–2326
(1995).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7836465</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hara K
et al.
Amino acid sufficiency and mTOR regulate p70 S6 kinase and eIF-4E
BP1 through a common effector mechanism. J. Biol.
Chem
273, 14484–14494
(1998).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9603962</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sancak Y
et al.
Ragulator–Rag complex targets mTORC1 to the lysosomal
surface and is necessary for its activation by amino acids.
Cell
141, 290–303
(2010).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3024592</ArticleId>
            <ArticleId IdType="pubmed">20381137</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bar-Peled L, Schweitzer LD, Zoncu R &amp; Sabatini DM
Ragulator is a GEF for the Rag GTPases that signal amino acid
levels to mTORC1. Cell
150, 1196–1208
(2012).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3517996</ArticleId>
            <ArticleId IdType="pubmed">22980980</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Su MY
et al.
Hybrid structure of the RagA/C–Ragulator mTORC1 activation
complex. Mol. Cell
68, 835–846
(2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5722659</ArticleId>
            <ArticleId IdType="pubmed">29107538</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shen K, Choe A &amp; Sabatini DM
Intersubunit crosstalk in the Rag GTPase heterodimer enables
mTORC1 to respond rapidly to amino acid availability.
Mol. Cell
68, 821 (2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5746184</ArticleId>
            <ArticleId IdType="pubmed">29149601</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rogala KB
et al.
Structural basis for the docking of mTORC1 on the lysosomal
surface. Science
366, 468–475
(2019).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7176403</ArticleId>
            <ArticleId IdType="pubmed">31601708</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bar-Peled L
et al.
A tumor suppressor complex with GAP activity for the Rag GTPases
that signal amino acid sufficiency to mTORC1.
Science
340, 1100–1106
(2013).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3728654</ArticleId>
            <ArticleId IdType="pubmed">23723238</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shen K, Valenstein ML, Gu X &amp; Sabatini DM
Arg-78 of Nprl2 catalyzes GATOR1-stimulated GTP hydrolysis by the
Rag GTPases. J. Biol. Chem
294, 2970–2975
(2019).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6393612</ArticleId>
            <ArticleId IdType="pubmed">30651352</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shen K
et al.
Architecture of the human GATOR1 and GATOR1–Rag GTPases
complexes. Nature
556, 64–69
(2018).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5975964</ArticleId>
            <ArticleId IdType="pubmed">29590090</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Peng M, Yin N &amp; Li MO
SZT2 dictates GATOR control of mTORC1 signalling.
Nature
543, 433–437
(2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5570594</ArticleId>
            <ArticleId IdType="pubmed">28199315</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wolfson RL
et al.
KICSTOR recruits GATOR1 to the lysosome and is necessary for
nutrients to regulate mTORC1. Nature
543, 438–442
(2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5360989</ArticleId>
            <ArticleId IdType="pubmed">28199306</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wolfson RL
et al.
Sestrin2 is a leucine sensor for the mTORC1
pathway. Science
351, 43–48
(2016).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4698017</ArticleId>
            <ArticleId IdType="pubmed">26449471</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Saxton RA
et al.
Structural basis for leucine sensing by the
Sestrin2–mTORC1 pathway. Science
351, 53–58
(2016).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4698039</ArticleId>
            <ArticleId IdType="pubmed">26586190</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ye J
et al.
GCN2 sustains mTORC1 suppression upon amino acid deprivation by
inducing Sestrin2. Genes Dev.
29, 2331–2336
(2015).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4691887</ArticleId>
            <ArticleId IdType="pubmed">26543160</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chantranupong L
et al.
The Sestrins interact with GATOR2 to negatively regulate the
amino-acid-sensing pathway upstream of mTORC1. Cell
Rep. 9, 1–8
(2014).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4223866</ArticleId>
            <ArticleId IdType="pubmed">25263562</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Parmigiani A
et al.
Sestrins inhibit mTORC1 kinase activation through the GATOR
complex. Cell Rep. 9,
1281–1291
(2014).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4303546</ArticleId>
            <ArticleId IdType="pubmed">25457612</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chantranupong L
et al.
The CASTOR proteins are arginine sensors for the mTORC1
pathway. Cell
165, 153–164
(2016).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4808398</ArticleId>
            <ArticleId IdType="pubmed">26972053</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Saxton RA, Chantranupong L, Knockenhauer KE, Schwartz TU &amp; Sabatini DM
Mechanism of arginine sensing by CASTOR1 upstream of
mTORC1. Nature
536, 229–233
(2016).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4988899</ArticleId>
            <ArticleId IdType="pubmed">27487210</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rebsamen M
et al.
SLC38A9 is a component of the lysosomal amino acid sensing
machinery that controls mTORC1. Nature
519, 477–481
(2015).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4376665</ArticleId>
            <ArticleId IdType="pubmed">25561175</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang S
et al.
Lysosomal amino acid transporter SLC38A9 signals arginine
sufficiency to mTORC1. Science
347, 188–194
(2015).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4295826</ArticleId>
            <ArticleId IdType="pubmed">25567906</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lei HT, Ma J, Sanchez Martinez S &amp; Gonen T
Crystal structure of arginine-bound lysosomal transporter SLC38A9
in the cytosol-open state. Nat. Struct. Mol.
Biol
25, 522–527
(2018).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7346717</ArticleId>
            <ArticleId IdType="pubmed">29872228</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shen K &amp; Sabatini DM
Ragulator and SLC38A9 activate the Rag GTPases through
noncanonical GEF mechanisms. Proc. Natl Acad. Sci.
USA
115, 9545–9550
(2018).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6156610</ArticleId>
            <ArticleId IdType="pubmed">30181260</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zoncu R
et al.
mTORC1 senses lysosomal amino acids through an inside-out
mechanism that requires the vacuolar H+-ATPase.
Science
334, 678–683
(2011).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3211112</ArticleId>
            <ArticleId IdType="pubmed">22053050</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Petit CS, Roczniak-Ferguson A &amp; Ferguson SM
Recruitment of folliculin to lysosomes supports the amino
acid-dependent activation of Rag GTPases. J. Cell
Biol
202, 1107–1122
(2013).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3787382</ArticleId>
            <ArticleId IdType="pubmed">24081491</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tsun ZY
et al.
The folliculin tumor suppressor is a GAP for the RagC/D GTPases
that signal amino acid levels to mTORC1. Mol.
Cell
52, 495–505
(2013).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3867817</ArticleId>
            <ArticleId IdType="pubmed">24095279</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wada S
et al.
The tumor suppressor FLCN mediates an alternate mTOR pathway to
regulate browning of adipose tissue. Genes
Dev. 30,
2551–2564
(2016).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5159669</ArticleId>
            <ArticleId IdType="pubmed">27913603</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Villegas F
et al.
Lysosomal signaling licenses embryonic stem cell differentiation
via inactivation of Tfe3. Cell Stem Cell
24, 257–270.e8
(2019).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30595499</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Perera RM
et al.
Transcriptional control of autophagy-lysosome function drives
pancreatic cancer metabolism. Nature
524, 361–365
(2015).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5086585</ArticleId>
            <ArticleId IdType="pubmed">26168401</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Di Malta C
et al.
Transcriptional activation of RagD GTPase controls mTORC1 and
promotes cancer growth. Science
356, 1188–1192
(2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5730647</ArticleId>
            <ArticleId IdType="pubmed">28619945</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gu X
et al.
SAMTOR is an S-adenosylmethionine sensor for the mTORC1
pathway. Science
358, 813–818
(2017). </Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5747364</ArticleId>
            <ArticleId IdType="pubmed">29123071</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Efeyan A
et al.
Regulation of mTORC1 by the Rag GTPases is necessary for neonatal
autophagy and survival. Nature
493, 679–683
(2013).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4000705</ArticleId>
            <ArticleId IdType="pubmed">23263183</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kalender A
et al.
Metformin, independent of AMPK, inhibits mTORC1 in a rag
GTPase-dependent manner. Cell Metab.
11, 390–401
(2010).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3081779</ArticleId>
            <ArticleId IdType="pubmed">20444419</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hoxhaj G
et al.
The mTORC1 signaling network senses changes in cellular purine
nucleotide levels. Cell Rep.
21, 1331–1346
(2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5689476</ArticleId>
            <ArticleId IdType="pubmed">29091770</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Emmanuel N
et al.
Purine nucleotide availability regulates mTORC1 activity through
the Rheb GTPase. Cell Rep.
19, 2665–2680
(2017). </Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28658616</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Menon D
et al.
Lipid sensing by mTOR via de novo synthesis of phosphatidic
acid. J. Biol. Chem
292, 6303–6311
(2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5391759</ArticleId>
            <ArticleId IdType="pubmed">28223357</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jewell JL
et al.
Differential regulation of mTORC1 by leucine and
glutamine. Science
347, 194 (2015).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4384888</ArticleId>
            <ArticleId IdType="pubmed">25567907</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gan X, Wang J, Su B &amp; Wu D
Evidence for direct activation of mTORC2 kinase activity by
phosphatidylinositol 3,4,5-trisphosphate. J. Biol.
Chem
286, 10998–11002
(2011).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3064154</ArticleId>
            <ArticleId IdType="pubmed">21310961</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Khanna A
et al.
The small GTPases Ras and Rap1 bind to and control TORC2
activity. Sci. Rep
6, 25823 (2016).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4865869</ArticleId>
            <ArticleId IdType="pubmed">27172998</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Saci A, Cantley Lewis, C. &amp; Carpenter Christopher L.
Rac1 regulates the activity of mTORC1 and mTORC2 and controls
cellular size. Mol. Cell
42, 50–61
(2011).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3750737</ArticleId>
            <ArticleId IdType="pubmed">21474067</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Senoo H
et al.
Phosphorylated Rho–GDP directly activates mTORC2 kinase
towards AKT through dimerization with Ras–GTP to regulate cell
migration. Nat. Cell Biol
21, 867–878
(2019).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6650273</ArticleId>
            <ArticleId IdType="pubmed">31263268</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kovalski JR
et al.
The functional proximal proteome of oncogenic Ras includes
mTORC2. Mol. Cell
73, 830–844
(2019). </Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6386588</ArticleId>
            <ArticleId IdType="pubmed">30639242</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Um SH
et al.
Absence of S6K1 protects against age- and diet-induced obesity
while enhancing insulin sensitivity. Nature
431, 200–205
(2004).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15306821</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hsu PP
et al.
The mTOR-regulated phosphoproteome reveals a mechanism of
mTORC1-mediated inhibition of growth factor signaling.
Science
332, 1317–1322
(2011).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3177140</ArticleId>
            <ArticleId IdType="pubmed">21659604</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu Y
et al.
Phosphoproteomic analysis identifies Grb10 as an mTORC1 substrate
that negatively regulates insulin signaling.
Science
332, 1322–1326
(2011).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3195509</ArticleId>
            <ArticleId IdType="pubmed">21659605</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kazyken D
et al.
AMPK directly activates mTORC2 to promote cell survival during
acute energetic stress. Sci. Signal
12, eaav3249
(2019).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6935248</ArticleId>
            <ArticleId IdType="pubmed">31186373</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cross DA, Alessi DR, Cohen P, Andjelkovich M &amp; Hemmings BA
Inhibition of glycogen synthase kinase-3 by insulin mediated by
protein kinase B. Nature
378, 785–789
(1995).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8524413</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sengupta S, Peterson TR, Laplante M, Oh S &amp; Sabatini DM
mTORC1 controls fasting-induced ketogenesis and its modulation by
ageing. Nature
468, 1100–1104
(2010).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21179166</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Komatsu M
et al.
Impairment of starvation-induced and constitutive autophagy in
Atg7-deficient mice. J. Cell Biol
169, 425 (2005).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2171928</ArticleId>
            <ArticleId IdType="pubmed">15866887</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Peng M, Yin N &amp; Li MO
Sestrins function as guanine nucleotide dissociation inhibitors
for Rag GTPases to control mTORC1 signaling.
Cell
159, 122–133
(2014).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4181352</ArticleId>
            <ArticleId IdType="pubmed">25259925</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kuma A
et al.
The role of autophagy during the early neonatal starvation
period. Nature
432, 1032–1036
(2004).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15525940</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tontonoz P, Hu E &amp; Spiegelman BM
Stimulation of adipogenesis in fibroblasts by PPARγ2, a
lipid-activated transcription factor. Cell
79, 1147–1156
(1994).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8001151</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arif A
et al.
EPRS is a critical mTORC1–S6K1 effector that influences
adiposity in mice. Nature
542, 357–361
(2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5480610</ArticleId>
            <ArticleId IdType="pubmed">28178239</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee PL, Tang Y, Li H &amp; Guertin DA
Raptor/mTORC1 loss in adipocytes causes progressive lipodystrophy
and fatty liver disease. Mol. Metab
5, 422–432
(2016).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4877665</ArticleId>
            <ArticleId IdType="pubmed">27257602</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Polak P
et al.
Adipose-specific knockout of raptor results in lean mice with
enhanced mitochondrial respiration. Cell
Metab. 8,
399–410
(2008).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19046571</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hagiwara A
et al.
Hepatic mTORC2 activates glycolysis and lipogenesis through Akt,
glucokinase, and SREBP1c. Cell Metab.
15, 725–738
(2012).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22521878</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yuan M, Pino E, Wu L, Kacergis M &amp; Soukas AA
Identification of Akt-independent regulation of hepatic
lipogenesis by mammalian target of rapamycin (mTOR) complex
2. J. Biol. Chem
287, 29579–29588
(2012).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3436168</ArticleId>
            <ArticleId IdType="pubmed">22773877</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Puigserver P
et al.
Insulin-regulated hepatic gluconeogenesis through
FOXO1–PGC-1α interaction.
Nature
423, 550–555
(2003).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12754525</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Howell JJ
et al.
Metformin inhibits hepatic mTORC1 signaling via dose-dependent
mechanisms involving AMPK and the TSC complex. Cell
Metab. 25,
463–471
(2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5299044</ArticleId>
            <ArticleId IdType="pubmed">28089566</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lipton JO &amp; Sahin M
The neurology of mTOR. Neuron
84, 275–291
(2014).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4223653</ArticleId>
            <ArticleId IdType="pubmed">25374355</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Graber TE, McCamphill PK &amp; Sossin WS
A recollection of mTOR signaling in learning and
memory. Learn Mem. 20,
518–530
(2013).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24042848</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cloetta D
et al.
Inactivation of mTORC1 in the developing brain causes
microcephaly and affects gliogenesis. J.
Neurosci
33, 7799–7810
(2013).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6618947</ArticleId>
            <ArticleId IdType="pubmed">23637172</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thomanetz V
et al.
Ablation of the mTORC2 component rictor in brain or Purkinje
cells affects size and neuron morphology. J. Cell
Biol
201, 293–308
(2013).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3628512</ArticleId>
            <ArticleId IdType="pubmed">23569215</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Crino PB
mTOR signaling in epilepsy: insights from malformations of
cortical development. Cold Spring Harb. Perspect.
Med
5, a022442 (2015).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4382721</ArticleId>
            <ArticleId IdType="pubmed">25833943</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pilarski R
et al.
Cowden syndrome and the PTEN hamartoma tumor syndrome: systematic
review and revised diagnostic criteria. J. Natl
Cancer Inst
105, 1607–1616
(2013).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24136893</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Puffenberger EG
et al.
Polyhydramnios, megalencephaly and symptomatic epilepsy caused by
a homozygous 7-kilobase deletion in LYK5.
Brain
130, 1929–1941
(2007).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17522105</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dibbens LM
et al.
Mutations in DEPDC5 cause familial focal epilepsy with variable
foci. Nat. Genet
45, 546 (2013).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23542697</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weckhuysen S
et al.
Involvement of GATOR complex genes in familial focal epilepsies
and focal cortical dysplasia. Epilepsia
57, 994–1003
(2016).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27173016</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yuskaitis CJ
et al.
A mouse model of DEPDC5-related epilepsy: neuronal loss of Depdc5
causes dysplastic and ectopic neurons, increased mTOR signaling, and seizure
susceptibility. Neurobiol. Dis
111, 91–101
(2018).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5803417</ArticleId>
            <ArticleId IdType="pubmed">29274432</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Basel-Vanagaite L
et al.
Biallelic SZT2 mutations cause infantile encephalopathy with
epilepsy and dysmorphic corpus callosum. Am. J. Hum.
Genet
93, 524–529
(2013).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3769928</ArticleId>
            <ArticleId IdType="pubmed">23932106</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nakamura Y
et al.
Constitutive activation of mTORC1 signaling induced by biallelic
loss-of-function mutations in SZT2 underlies a discernible
neurodevelopmental disease. PLOS ONE
14, e0221482
(2019).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6701784</ArticleId>
            <ArticleId IdType="pubmed">31430354</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reijnders MRF
et al.
Variation in a range of mTOR-related genes associates with
intracranial volume and intellectual disability.
Nat. Commun
8, 1052 (2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5648772</ArticleId>
            <ArticleId IdType="pubmed">29051493</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Allen AS
et al.
De novo mutations in epileptic encephalopathies.
Nature
501, 217–221
(2013).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3773011</ArticleId>
            <ArticleId IdType="pubmed">23934111</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>D’Gama AM
et al.
Somatic mutations activating the mTOR pathway in dorsal
telencephalic progenitors cause a continuum of cortical
dysplasias. Cell Rep. 21,
3754–3766
(2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5752134</ArticleId>
            <ArticleId IdType="pubmed">29281825</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gallent EA &amp; Steward O
Neuronal PTEN deletion in adult cortical neurons triggers
progressive growth of cell bodies, dendrites, and axons.
Exp. Neurol
303, 12–28
(2018).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5864555</ArticleId>
            <ArticleId IdType="pubmed">29337147</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abs E
et al.
TORC1-dependent epilepsy caused by acute biallelic Tsc1 deletion
in adult mice. Ann. Neurol
74, 569–579
(2013).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23720219</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McDaniel SS, Rensing NR, Thio LL, Yamada KA &amp; Wong M
The ketogenic diet inhibits the mammalian target of rapamycin
(mTOR) pathway. Epilepsia
52, e7–e11
(2011).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3076631</ArticleId>
            <ArticleId IdType="pubmed">21371020</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>US National Library of
Medicine. ClinicalTrials.gov
https://clinicaltrials.gov/show/NCT01713946
(2017).</Citation>
        </Reference>
        <Reference>
          <Citation>Brandt C
et al.
The novel, catalytic mTORC1/2 inhibitor PQR620 and the
PI3K/mTORC1/2 inhibitor PQR530 effectively cross the blood–brain
barrier and increase seizure threshold in a mouse model of chronic
epilepsy. Neuropharmacology
140, 107–120
(2018).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30081001</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hsu W-L
et al.
Glutamate stimulates local protein synthesis in the axons of rat
cortical neurons by activating
α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors
and metabotropic glutamate receptors. J. Biol.
Chem
290, 20748–20760
(2015).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4543638</ArticleId>
            <ArticleId IdType="pubmed">26134564</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Park KK
et al.
Promoting axon regeneration in the adult CNS by modulation of the
PTEN/mTOR pathway. Science
322, 963 (2008).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2652400</ArticleId>
            <ArticleId IdType="pubmed">18988856</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Autry AE
et al.
NMDA receptor blockade at rest triggers rapid behavioural
antidepressant responses. Nature
475, 91–95
(2011).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3172695</ArticleId>
            <ArticleId IdType="pubmed">21677641</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Takei N
et al.
Brain-derived neurotrophic factor induces mammalian target of
rapamycin-dependent local activation of translation machinery and protein
synthesis in neuronal dendrites. J.
Neurosci
24, 9760–9769
(2004).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6730227</ArticleId>
            <ArticleId IdType="pubmed">15525761</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Henry FE, Hockeimer W, Chen A, Mysore SP &amp; Sutton MA
Mechanistic target of rapamycin is necessary for changes in
dendritic spine morphology associated with long-term
potentiation. Mol. Brain
10, 50–50
(2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5663037</ArticleId>
            <ArticleId IdType="pubmed">29084578</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tsai PT
et al.
Autistic-like behaviour and cerebellar dysfunction in Purkinje
cell Tsc1 mutant mice. Nature
488, 647–651
(2012).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3615424</ArticleId>
            <ArticleId IdType="pubmed">22763451</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gkogkas CG
et al.
Autism-related deficits via dysregulated eIF4E-dependent
translational control. Nature
493, 371–377
(2013).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4133997</ArticleId>
            <ArticleId IdType="pubmed">23172145</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li N
et al.
mTOR-dependent synapse formation underlies the rapid
antidepressant effects of NMDA antagonists.
Science
329, 959 (2010). </Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3116441</ArticleId>
            <ArticleId IdType="pubmed">20724638</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kato T
et al.
Sestrin modulator NV-5138 produces rapid antidepressant effects
via direct mTORC1 activation. J. Clin.
Invest
129, 2542–2554
(2019).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6546461</ArticleId>
            <ArticleId IdType="pubmed">30990795</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nikoletopoulou V, Sidiropoulou K, Kallergi E, Dalezios Y &amp; Tavernarakis N
Modulation of autophagy by BDNF underlies synaptic
plasticity. Cell Metab.
26, 230–242
(2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28683289</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tang G
et al.
Loss of mTOR-dependent macroautophagy causes autistic-like
synaptic pruning deficits. Neuron
83, 1131–1143
(2014).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4159743</ArticleId>
            <ArticleId IdType="pubmed">25155956</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Menon S &amp; Manning BD
Common corruption of the mTOR signaling network in human
tumors. Oncogene
27, S43–S51
(2008).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3752670</ArticleId>
            <ArticleId IdType="pubmed">19956179</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Okosun J
et al.
Recurrent mTORC1-activating RRAGC mutations in follicular
lymphoma. Nat. Genet
48, 183–188
(2016).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4731318</ArticleId>
            <ArticleId IdType="pubmed">26691987</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nickerson ML
et al.
Mutations in a novel gene lead to kidney tumors, lung wall
defects, and benign tumors of the hair follicle in patients with the
Birt–Hogg–Dube syndrome. Cancer
Cell
2, 157–164
(2002).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12204536</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wagle N
et al.
Activating mTOR mutations in a patient with an extraordinary
response on a phase I trial of everolimus and pazopanib.
Cancer Discov. 4,
546–553
(2014).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4122326</ArticleId>
            <ArticleId IdType="pubmed">24625776</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tabernero J
et al.
Dose- and schedule-dependent inhibition of the mammalian target
of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study
in patients with advanced solid tumors. J. Clin.
Oncol
26, 1603–1610
(2008).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18332469</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Palm W
et al.
The utilization of extracellular proteins as nutrients is
suppressed by mTORC1. Cell
162, 259–270
(2015).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4506698</ArticleId>
            <ArticleId IdType="pubmed">26144316</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Feldman ME
et al.
Active-site inhibitors of mTOR target rapamycin-resistant outputs
of mTORC1 and mTORC2. PLOS Biol.
7, e1000038
(2009).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2637922</ArticleId>
            <ArticleId IdType="pubmed">19209957</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Garcia-Martinez JM
et al.
Ku-0063794 is a specific inhibitor of the mammalian target of
rapamycin (mTOR). Biochem. J
421, 29–42
(2009).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2708931</ArticleId>
            <ArticleId IdType="pubmed">19402821</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ghobrial IM
et al.
TAK-228 (formerly MLN0128), an investigational oral dual TORC1/2
inhibitor: a phase I dose escalation study in patients with relapsed or
refractory multiple myeloma, non-Hodgkin lymphoma, or
Waldenström’s macroglobulinemia. Am.
J. Hematol
91, 400–405
(2016).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26800393</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rodrik-Outmezguine VS
et al.
mTOR kinase inhibition causes feedback-dependent biphasic
regulation of AKT signaling. Cancer Discov.
1, 248–259
(2011).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3227125</ArticleId>
            <ArticleId IdType="pubmed">22140653</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rodrik-Outmezguine VS
et al.
Overcoming mTOR resistance mutations with a new-generation mTOR
inhibitor. Nature
534, 272–276
(2016).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4902179</ArticleId>
            <ArticleId IdType="pubmed">27279227</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fan Q
et al.
A kinase inhibitor targeted to mTORC1 drives regression in
glioblastoma. Cancer Cell
31, 424–435
(2017). </Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5386178</ArticleId>
            <ArticleId IdType="pubmed">28292440</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kaeberlein M
et al.
Regulation of yeast replicative life span by TOR and Sch9 in
response to nutrients. Science
310, 1193–1196
(2005).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16293764</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vellai T
et al.
Genetics: influence of TOR kinase on lifespan in C.
elegans. Nature
426, 620 (2003).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14668850</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jia K, Chen D &amp; Riddle DL
The TOR pathway interacts with the insulin signaling pathway to
regulate C. elegans larval development, metabolism and life
span. Development
131, 3897–3906
(2004).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15253933</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kapahi P
et al.
Regulation of lifespan in Drosophila by modulation of genes in
the TOR signaling pathway. Curr. Biol
14, 885–890
(2004).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2754830</ArticleId>
            <ArticleId IdType="pubmed">15186745</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu JJ
et al.
Increased mammalian lifespan and a segmental and tissue-specific
slowing of aging after genetic reduction of mTOR expression.
Cell Rep. 4,
913–920
(2013).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3784301</ArticleId>
            <ArticleId IdType="pubmed">23994476</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Harrison DE
et al.
Rapamycin fed late in life extends lifespan in genetically
heterogeneous mice. Nature
460, 392–395
(2009). </Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2786175</ArticleId>
            <ArticleId IdType="pubmed">19587680</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Powers RW 3rd, Kaeberlein M, Caldwell SD, Kennedy BK &amp; Fields S
Extension of chronological life span in yeast by decreased TOR
pathway signaling. Genes Dev.
20, 174–184
(2006).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1356109</ArticleId>
            <ArticleId IdType="pubmed">16418483</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Robida-Stubbs S
et al.
TOR signaling and rapamycin influence longevity by regulating
SKN-1/Nrf and DAF-16/FoxO. Cell Metab.
15, 713–724
(2012).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3348514</ArticleId>
            <ArticleId IdType="pubmed">22560223</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bjedov I
et al.
Mechanisms of life span extension by rapamycin in the fruit fly
Drosophila melanogaster. Cell
Metab. 11,
35–46
(2010).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2824086</ArticleId>
            <ArticleId IdType="pubmed">20074526</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bitto A
et al.
Transient rapamycin treatment can increase lifespan and
healthspan in middle-aged mice. eLife
5, e16351 (2016).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4996648</ArticleId>
            <ArticleId IdType="pubmed">27549339</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hansen M
et al.
Lifespan extension by conditions that inhibit translation in
Caenorhabditis elegans. Aging
Cell
6, 95–110
(2007).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17266679</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grandison RC, Piper MDW &amp; Partridge L
Amino-acid imbalance explains extension of lifespan by dietary
restriction in Drosophila. Nature
462, 1061–1064
(2009).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2798000</ArticleId>
            <ArticleId IdType="pubmed">19956092</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Selman C
et al.
Ribosomal protein S6 kinase 1 signaling regulates mammalian life
span. Science
326, 140–144
(2009).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4954603</ArticleId>
            <ArticleId IdType="pubmed">19797661</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hansen M, Rubinsztein DC &amp; Walker DW
Autophagy as a promoter of longevity: insights from model
organisms. Nat. Rev. Mol. Cell Biol
19, 579–593
(2018).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6424591</ArticleId>
            <ArticleId IdType="pubmed">30006559</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fernandez AF
et al.
Disruption of the beclin 1–BCL2 autophagy regulatory
complex promotes longevity in mice. Nature
558, 136–140
(2018).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5992097</ArticleId>
            <ArticleId IdType="pubmed">29849149</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Toth ML
et al.
Longevity pathways converge on autophagy genes to regulate life
span in Caenorhabditis elegans.
Autophagy
4, 330–338
(2008).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18219227</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hansen M
et al.
A role for autophagy in the extension of lifespan by dietary
restriction in C. elegans. PLOS
Genet. 4, e24
(2008).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2242811</ArticleId>
            <ArticleId IdType="pubmed">18282106</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen C, Liu Y, Liu Y &amp; Zheng P
mTOR regulation and therapeutic rejuvenation of aging
hematopoietic stem cells. Sci. Signal
2, ra75 (2009).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4020596</ArticleId>
            <ArticleId IdType="pubmed">19934433</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yilmaz OH
et al.
mTORC1 in the Paneth cell niche couples intestinal stem-cell
function to calorie intake. Nature
486, 490–495
(2012).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3387287</ArticleId>
            <ArticleId IdType="pubmed">22722868</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Carroll B
et al.
Persistent mTORC1 signaling in cell senescence results from
defects in amino acid and growth factor sensing. J.
Cell Biol
216, 1949 (2017). </Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5496614</ArticleId>
            <ArticleId IdType="pubmed">28566325</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Laberge RM
et al.
MTOR regulates the pro-tumorigenic senescence-associated
secretory phenotype by promoting IL1A translation.
Nat. Cell Biol
17, 1049–1061
(2015).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4691706</ArticleId>
            <ArticleId IdType="pubmed">26147250</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Herranz N
et al.
mTOR regulates MAPKAPK2 translation to control the
senescence-associated secretory phenotype. Nat. Cell
Biol
17, 1205–1217
(2015).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4589897</ArticleId>
            <ArticleId IdType="pubmed">26280535</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arriola Apelo SI
et al.
Alternative rapamycin treatment regimens mitigate the impact of
rapamycin on glucose homeostasis and the immune system.
Aging Cell
15, 28–38
(2016).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4717280</ArticleId>
            <ArticleId IdType="pubmed">26463117</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arriola Apelo SI, Pumper CP, Baar EL, Cummings NE &amp; Lamming DW
Intermittent administration of rapamycin extends the life span of
female C57BL/6J mice. J. Gerontol. A Biol. Sci. Med.
Sci
71, 876–881
(2016).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4906329</ArticleId>
            <ArticleId IdType="pubmed">27091134</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mannick JB
et al.
TORC1 inhibition enhances immune function and reduces infections
in the elderly. Sci. Transl. Med
10, eaaq1564
(2018).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29997249</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lim C-Y
et al.
ER–lysosome contacts enable cholesterol sensing by mTORC1
and drive aberrant growth signalling in Niemann–Pick type
C. Nat. Cell Biol
21, 1206–1218
(2019).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6936960</ArticleId>
            <ArticleId IdType="pubmed">31548609</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hao F
et al.
Rheb localized on the Golgi membrane activates lysosome-localized
mTORC1 at the Golgi–lysosome contact site. J.
Cell Sci
131, jcs208017
(2018).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29222112</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Korolchuk VI
et al.
Lysosomal positioning coordinates cellular nutrient
responses. Nat. Cell Biol
13, 453–460
(2011).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3071334</ArticleId>
            <ArticleId IdType="pubmed">21394080</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Manifava M
et al.
Dynamics of mTORC1 activation in response to amino
acids. eLife
5, e19960 (2016).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5059141</ArticleId>
            <ArticleId IdType="pubmed">27725083</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ahmed AR
et al.
Direct imaging of the recruitment and phosphorylation of S6K1 in
the mTORC1 pathway in living cells. Sci.
Rep
9, 3408 (2019).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6399282</ArticleId>
            <ArticleId IdType="pubmed">30833605</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Naito T, Kuma A &amp; Mizushima N
Differential contribution of insulin and amino acids to the
mTORC1–autophagy pathway in the liver and muscle.
J. Biol. Chem
288, 21074–21081
(2013).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3774374</ArticleId>
            <ArticleId IdType="pubmed">23744068</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Frey JW, Jacobs BL, Goodman CA &amp; Hornberger TA
A role for Raptor phosphorylation in the mechanical activation of
mTOR signaling. Cell Signal.
26, 313–322
(2014).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3917221</ArticleId>
            <ArticleId IdType="pubmed">24239769</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>You JS
et al.
The role of raptor in the mechanical load-induced regulation of
mTOR signaling, protein synthesis, and skeletal muscle
hypertrophy. FASEB J. 33,
4021–4034
(2019).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6404572</ArticleId>
            <ArticleId IdType="pubmed">30509128</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jacobs BL
et al.
Eccentric contractions increase the phosphorylation of tuberous
sclerosis complex-2 (TSC2) and alter the targeting of TSC2 and the
mechanistic target of rapamycin to the lysosome. J.
Physiol
591, 4611–4620
(2013).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3784202</ArticleId>
            <ArticleId IdType="pubmed">23732640</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang A
et al.
Activity-independent targeting of mTOR to lysosomes in primary
osteoclasts. Sci. Rep
7, 3005 (2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5462732</ArticleId>
            <ArticleId IdType="pubmed">28592812</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stracka D, Jozefczuk S, Rudroff F, Sauer U &amp; Hall MN
Nitrogen source activates TOR (target of rapamycin) complex 1 via
glutamine and independently of Gtr/Rag proteins. J.
Biol. Chem
289, 25010–25020
(2014). </Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4155668</ArticleId>
            <ArticleId IdType="pubmed">25063813</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Urano J, Tabancay AP, Yang W &amp; Tamanoi F
The Saccharomyces cerevisiae Rheb G-protein is
involved in regulating canavanine resistance and arginine
uptake. J. Biol. Chem
275, 11198–11206
(2000).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10753927</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Otsubo Y &amp; Yamamato M
TOR signaling in fission yeast. Crit.
Rev. Biochem. Mol. Biol
43, 277–283
(2008).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18756382</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wolfson RL &amp; Sabatini DM
The dawn of the age of amino acid sensors for the mTORC1
pathway. Cell Metab. 26,
301–309
(2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5560103</ArticleId>
            <ArticleId IdType="pubmed">28768171</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Piyankarage SC, Augustin H, Grosjean Y, Featherstone DE &amp; Shippy SA
Hemolymph amino acid analysis of individual Drosophila
larvae. Anal. Chem
80, 1201–1207
(2008).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2267754</ArticleId>
            <ArticleId IdType="pubmed">18193891</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Algret R
et al.
Molecular architecture and function of the SEA complex, a
modulator of the TORC1 pathway. Mol. Cell
Proteom
13, 2855 (2014).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4223477</ArticleId>
            <ArticleId IdType="pubmed">25073740</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nixon RA
The role of autophagy in neurodegenerative
disease. Nat. Med
19, 983 (2013).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23921753</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nixon RA
et al.
Extensive involvement of autophagy in Alzheimer disease: an
immuno-electron microscopy study. J. Neuropathol.
Exp. Neurol
64, 113–122
(2005).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15751225</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tanik SA, Schultheiss CE, Volpicelli-Daley LA, Brunden KR &amp; Lee VMY
Lewy body-like α-Synuclein aggregates resist degradation
and impair macroautophagy. J. Biol. Chem
288, 15194–15210
(2013).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3663539</ArticleId>
            <ArticleId IdType="pubmed">23532841</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Komatsu M
et al.
Loss of autophagy in the central nervous system causes
neurodegeneration in mice. Nature
441, 880–884
(2006).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16625205</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hara T
et al.
Suppression of basal autophagy in neural cells causes
neurodegenerative disease in mice. Nature
441, 885–889
(2006).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16625204</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kaeberlein M &amp; Galvan V
Rapamycin and Alzheimer’s disease: time for a clinical
trial?
Sci. Transl. Med
11, eaar4289
(2019).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6762017</ArticleId>
            <ArticleId IdType="pubmed">30674654</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dehay B
et al.
Pathogenic lysosomal depletion in Parkinson’s
disease. J. Neurosci
30, 12535 (2010).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6633458</ArticleId>
            <ArticleId IdType="pubmed">20844148</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Santini E, Heiman M, Greengard P, Valjent E &amp; Fisone G
Inhibition of mTOR signaling in Parkinson’s disease
prevents L-DOPA-induced dyskinesia. Sci.
Signal
2, ra36 (2009).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19622833</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Castellano BM
et al.
Lysosomal cholesterol activates mTORC1 via an
SLC38A9-Niemann–Pick C1 signaling complex.
Science
355, 1306–1311
(2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5823611</ArticleId>
            <ArticleId IdType="pubmed">28336668</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
